AU2020276500A1 - Humanized anti-CD137 antibodies and uses thereof - Google Patents

Humanized anti-CD137 antibodies and uses thereof Download PDF

Info

Publication number
AU2020276500A1
AU2020276500A1 AU2020276500A AU2020276500A AU2020276500A1 AU 2020276500 A1 AU2020276500 A1 AU 2020276500A1 AU 2020276500 A AU2020276500 A AU 2020276500A AU 2020276500 A AU2020276500 A AU 2020276500A AU 2020276500 A1 AU2020276500 A1 AU 2020276500A1
Authority
AU
Australia
Prior art keywords
antibody
seq
amino acid
humanized
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020276500A
Other languages
English (en)
Inventor
Jieyi Wang
Yi Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lyvgen Biopharma Holdings Ltd
Original Assignee
Lyvgen Biopharma Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyvgen Biopharma Holdings Ltd filed Critical Lyvgen Biopharma Holdings Ltd
Publication of AU2020276500A1 publication Critical patent/AU2020276500A1/en
Assigned to LYVGEN BIOPHARMA HOLDINGS LIMITED reassignment LYVGEN BIOPHARMA HOLDINGS LIMITED Request for Assignment Assignors: Lyvgen Biopharma (Suzhou) Co., Ltd., LYVGEN BIOPHARMA CO., LTD.
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2020276500A 2019-05-10 2020-05-08 Humanized anti-CD137 antibodies and uses thereof Pending AU2020276500A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019086364 2019-05-10
CNPCT/CN2019/086364 2019-05-10
PCT/US2020/032095 WO2020231809A1 (en) 2019-05-10 2020-05-08 Humanized anti-cd137 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
AU2020276500A1 true AU2020276500A1 (en) 2021-12-16

Family

ID=73289535

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020276500A Pending AU2020276500A1 (en) 2019-05-10 2020-05-08 Humanized anti-CD137 antibodies and uses thereof

Country Status (8)

Country Link
US (1) US11203643B2 (https=)
EP (1) EP3966252A4 (https=)
JP (1) JP7682102B2 (https=)
KR (1) KR20220008306A (https=)
CN (1) CN114026120B (https=)
AU (1) AU2020276500A1 (https=)
CA (1) CA3139274A1 (https=)
WO (1) WO2020231809A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018183520A1 (en) * 2017-03-28 2018-10-04 Lyvgen Biopharma Holdings Limited Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
WO2019109238A1 (en) 2017-12-05 2019-06-13 Lyvgen Biopharma Co., Ltd. Anti-cd137 antibodies and uses thereof
CN117843786A (zh) * 2019-11-19 2024-04-09 非同（成都）生物科技有限公司 人源化4-1bb单克隆抗体及其药物组合物
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303121B1 (en) * 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
KR20000034847A (ko) * 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
AU2002364935A1 (en) 2001-10-09 2003-06-23 Mayo Foundation For Medical Education And Research Enhancement of immune responses by 4-1bb-binding agents
US20030223989A1 (en) 2002-04-18 2003-12-04 Pluenneke John D. CD137 agonists to treat patients with IgE-mediated conditions
PL375144A1 (en) * 2002-07-30 2005-11-28 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
CN1997667A (zh) * 2004-05-10 2007-07-11 宏观基因有限公司 人源化FcγRⅡB特异性抗体及其使用方法
US20070253961A1 (en) 2004-06-09 2007-11-01 Ulsan Industrial Education Foundation Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis
US20060171929A1 (en) * 2005-01-31 2006-08-03 The University Of Washington Regulation of dendritic cell functions by the DCAL-2 receptor
CA2609262A1 (en) 2005-06-03 2006-12-07 Mochida Pharmaceutical Co., Ltd. Anti-cd14 antibody fusion protein
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
PT2614082T (pt) 2010-09-09 2018-12-03 Pfizer Moléculas de ligação a 4-1bb
WO2014055967A2 (en) * 2012-10-05 2014-04-10 Neotope Biosciences Limited Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
CN104250302B (zh) * 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
AU2015264528A1 (en) 2014-05-21 2016-11-03 Kyowa Hakko Kirin Co., Ltd. Combination of an anti-CCR4 antibody and a 4-1BB agonist for treating cancer
US20170247455A1 (en) 2014-08-22 2017-08-31 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
WO2017068183A1 (en) 2015-10-23 2017-04-27 Apogenix Ag Single-chain cd137-receptor agonist proteins
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
EP3464362B1 (en) 2016-05-27 2020-12-09 AbbVie Biotherapeutics Inc. Anti-4-1bb antibodies and their uses
BR112019005895A2 (pt) * 2016-09-23 2019-06-11 Merus N.V. moléculas de ligação que modulam uma atividade biológica expressa por uma célula
MX395639B (es) * 2017-01-20 2025-03-25 Heidelberg Pharma Res Gmbh Composiciones y métodos para el agotamiento de células cd137+.
WO2018183520A1 (en) * 2017-03-28 2018-10-04 Lyvgen Biopharma Holdings Limited Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
EP3634485A4 (en) * 2017-06-07 2021-07-21 Silverback Therapeutics, Inc. CONJUGATES OF ANTIBODIES CONTAINING IMMUNOMODULATOR COMPOUNDS AND THEIR USES
WO2019109238A1 (en) * 2017-12-05 2019-06-13 Lyvgen Biopharma Co., Ltd. Anti-cd137 antibodies and uses thereof
CN107982538B (zh) * 2017-12-26 2021-10-22 深圳市体内生物医药科技有限公司 一种药物组合物及其应用
WO2020069382A1 (en) * 2018-09-28 2020-04-02 Lyvgen Biopharma Co., Ltd. Anti-cd137 binding molecules having engineered fc domains and therapeutic uses thereof
TWI839395B (zh) * 2018-10-09 2024-04-21 瑞士商Ｎｕｍａｂ治療公司 靶向cd137的抗體及其使用方法

Also Published As

Publication number Publication date
JP2022532173A (ja) 2022-07-13
US11203643B2 (en) 2021-12-21
CN114026120B (zh) 2024-03-19
KR20220008306A (ko) 2022-01-20
JP7682102B2 (ja) 2025-05-23
WO2020231809A1 (en) 2020-11-19
CA3139274A1 (en) 2020-11-19
US20210246218A1 (en) 2021-08-12
CN114026120A (zh) 2022-02-08
EP3966252A1 (en) 2022-03-16
EP3966252A4 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
US11203643B2 (en) Humanized anti-CD137 antibodies and uses thereof
US20220372155A1 (en) Anti-cd40 binding molecules and bi-specific antibodies comprising such
US11505615B2 (en) Anti-CD137 antibodies and uses thereof
WO2020065409A2 (en) Anti-cd40 binding molecules having engineered fc domains and therapeutic uses thereof
US20240218069A1 (en) Bi-specific antibodies comprising anti-b7h3 binding molecules
EP3856790A2 (en) Anti-cd40 binding molecules having engineered fc domains and therapeutic uses thereof
US20230406950A1 (en) Bi-specific antibodies comprising anti-cd137 binding molecules
US11976123B2 (en) Anti-CD40 antibodies and uses thereof
HK40068698A (zh) 人源化抗cd137抗体及其用途
HK40068698B (zh) 人源化抗cd137抗体及其用途
WO2025024646A1 (en) Multi-specific antibodies integrating dual immune modulating moieties and uses thereof in immunotherapy

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: LYVGEN BIOPHARMA HOLDINGS LIMITED

Free format text: FORMER APPLICANT(S): LYVGEN BIOPHARMA CO., LTD.; LYVGEN BIOPHARMA (SUZHOU) CO., LTD.